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of population-based cohort studies. Most of the currently 
available data comes from single-center, hospital-based stud-
ies. Several important cohort studies conducted in Western 
Europe and America have described the clinical course of 
CD.5-7 But there have been no well-designed cohort studies 
in Korea. Consequently, investigators are becoming aware 
of the need for a cohort study of CD in Korea. Moreover, ge-
netic or biomarker studies need blood or tissue specimens 
from a large number of patients, which should be collected 
together with accurate, matched clinical data. This highlights 
the urgent need for a nationwide collection of well-defined 
clinical characteristics of Korean CD patients and their bio-
logical specimens.
Attempts to comprehensively understand the epidemio-
logic, clinical, and genetic characteristics of Korean CD 
patients started in 2008. Won Ho Kim at Yonsei University, 
President of the Korean Association for the Study of Intes-
tinal Diseases (KASID) at that time, obtained a national 
grant, the “Research Network for Crohn’s Disease.” The four 
major aims of the study were as follows: (1) understand the 
epidemiologic and clinical characteristics by establishing a 
registered database of CD patients; (2) establish a genetic 
research management system and a genetic biobank by 
obtaining blood specimens and clinical data from CD pa-
tients; (3) establish a network of doctors specialized in CD 
treatment and patients with CD as a private non-profit or-
ganization; and (4) develop specific Korean diagnostic and 
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COMMENTARY
Crohn’s disease (CD) is a chronic, relapsing immune-
mediated inflammatory disorder of the intestine with un-
known causes. Both genetic and environmental factors are 
known to be involved in the pathogenesis of the disease.1 
The incidence and prevalence of CD have recently been 
increasing in Korea, probably secondary to environmental 
changes.2 To address this challenge, we need to understand 
the specific clinical and therapeutic characteristics of CD in 
Korean patients. It has been widely accepted that the phe-
notypes of IBD differ considerably between East Asians and 
Caucasians.3,4 Thus, the management strategies used for pa-
tients with CD in Western countries may not be appropriate 
for those in Korea. Therefore, it is crucial to understand the 
natural history and clinical characteristics of this disease in 
Korean patients, which are largely unknown due to the lack 
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therapeutic guidelines for CD. During the study period, clini-
cal data from nearly 2,000 blood specimens (both genomic 
DNA and sera) of 1,316 Korean CD patients were collected 
and stored at the Korean Green Cross Corporation. Active 
translational research by basic and clinical researchers is 
now underway using these samples.8,9 In addition, this study 
team established a nationwide doctor-patient network by 
hosting educational workshops for patients and sympo-
siums for clinicians via the regional society meetings every 
year (Seoul, Gyunggi, Daegu, and Daejeon). These provided 
disease information, life style education, counseling, and 
various programs for patients and their families, including 
one ensuring patients’ rights. This study team also estab-
lished and published the Korean diagnostic and therapeutic 
guidelines for CD with the help of the IBD Study Group of 
KASID10,11 that published the diagnostic guidelines for intes-
tinal tuberculosis, a disease often misdiagnosed as CD, in the 
same year.12 Through an e-mail survey, the IBD Study Group 
of KASID monitored the effectiveness of the diagnostic 
guidelines in clinical practice, investigated clinician satisfac-
tion with the guidelines, and collected feedback on ways to 
improve the guidelines.13 At that time, the chair of IBD study 
group was Professor Joo Sung Kim at Seoul National Univer-
sity.
After the nationally funded Research Network for Crohn’s 
Disease study ended, a better-designed cohort study involv-
ing prospective collection of clinical data was planned. The 
Korea Eisai Company sponsored a two-year educational 
grant for this CD cohort study. This study followed the Re-
search Network for Crohn’s Disease study and was named 
Establishment of Crohn’s disease in Korea and characteriza-
tion of clinical features with long-term follow-up, and was 
conducted from January 2012 to December 2013. This study 
team was led by Dong Soo Han, a Professor at the Hanyang 
University and the current vice president of KASID. Retro-
spective clinical data (for patients enrolled before 2009) and 
prospective clinical data (for patients enrolled during and 
after 2009) were collected in this study. The prospective pa-
tients were enrolled using a novel web-based eCRF system 
(www.cdcohort.org). Data for 1,388 retrospective patients 
and 890 prospective patients were collected and analyzed. 
A study coordinator monitored submission and quality of 
eCRF data. Blood specimens were collected from 635 of the 
prospective patients and stored in a deep freezer at -80oC. 
During this study, the IBD study group chair was Professor 
Young Ho Kim at the Sungkyunkwan University, who orga-
nized the clinical and translational studies that utilized these 
data. This study was registered at www.clinicaltrials.gov. The 
first results using the prospective data were presented dur-
ing the 2014 regular meeting of the European Crohn’s and 
Colitis Organization in Copenhagen, Denmark. The most 
important and innovative outcomes from this study were the 
establishment of a novel eCRF system to collect well-record-
ed, high-quality prospective data and the development of the 
associated data input protocol (the latter of which was led by 
Professor Byong Duk Ye).
In 2012, the Cardiovascular and Rare Disease Section, 
Korea Centers for Disease Control and Prevention (www.
cdc.go.kr) solicited grant applications for a 6-month demon-
stration project aimed at establishing a CD network (to run 
from August 2012 to December 2012). The KASID obtained 
this grant, and in 2012, for a 3-year national grant from the 
Korea Centers for Disease Control and Prevention. The new 
study funded by these grants was named Establishment and 
Management of Crohn’s Disease Research Network. The 
principal aim of this study was to broaden the pool of study 
subjects by recruiting additional investigators throughout 
Korea. Consequently, 28 institutions were recruited to par-
ticipate in this study. Currently, Professor Joo Sung Kim at 
the Seoul National University is in charge of the study. The 
Fig. 1. The progress of 3 studies integrated 
into the Crohn’s Disease Clinical Network 
and Cohort (CONNECT) study. KASID, Korean 
Association for the Study of Intestinal Dis-
eases.
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current chair of the IBD study group is Professor Kang Moon 
Lee at the Catholic University, and he is currently supervis-
ing the investigators and study projects working with the col-
lected data.
Recently, the latter two studies discussed above were inte-
grated into a single study referred to as the Crohn’s Disease 
Clinical Network and Cohort (CONNECT) study (Fig. 1). A 
total of 34 institutions are now participating in this study, and 
1,900 blood specimens have been collected. Four abstracts 
were presented at the regular KASID meeting in April 2014. 
From the CONNECT study, investigators anticipate that the 
typical clinical characteristics and genetic causes of CD in 
Korean patients will be elucidated. Additional diagnosis and 
treatment guidelines and therapeutic agents for Korean CD 
patients will be developed based on these data. Addition-
ally, we anticipate that after analysis, the collected data will 
be presented at international symposiums and the papers 
published. By following up with the registered patients, long-
term clinical characteristics and accuracy of initial diagnosis 
can also be investigated. Long-term follow-up results from 
the CONNECT study should help clinicians and research-
ers more accurately define CD prognosis in Korea, provide 
specific health care planning and education, and identify 
causative factors for CD in Korea, where the incidence of CD 
is rapidly increasing. 
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